January 13th 2021
Ryan Sullivan, MD, discusses treatment sequencing with targeted therapy and immunotherapy in melanoma.
January 11th 2021
Mario Sznol, MD, Yale Cancer Center, discusses the multidisciplinary management of toxicities associated with immunotherapy in patients with melanoma.
January 11th 2021
January 11, 2021 — The FDA has granted an orphan drug designation to the novel intratumoral immunotherapy agent PVSRIPO for the treatment of patients with advanced melanoma, specifically those with stage IIIB-IV disease.
January 7th 2021
Mario Sznol, MD, discusses toxicities associated with immunotherapy in patients with melanoma.
December 14th 2020
Mario Sznol, MD, discusses the critical importance of being aware of the immune-related toxicities that could arise when treating patients with cancer, along with the best ways to manage them.
December 7th 2020
In our exclusive interview, Caroline Robert, MD, PhD, discusses her groundbreaking work on clinical trials evaluating anti–CTLA-4 and anti–PD-1 antibodies in advanced melanoma, her experiences as a researcher in France and the United States, her love of traveling, and next steps for the field.
December 3rd 2020
Suthee Rapisuwon, MD, discusses the frontline treatment of acral and mucosal melanoma.
November 5th 2020
Douglas B. Johnson, MD, MSCI, discusses his research examining the impact of body composition on outcomes from anti–PD-1 with or without anti–CTLA-4 therapies in melanoma and other biomarkers under exploration.
October 8th 2020
Suthee Rapisuwon, MD, reviews management strategies under exploration for mucosal, acral, and uveal melanoma.
October 5th 2020
The immunotherapy combination of adjuvant nivolumab and ipilimumab failed to lead to a statistically significant improvement in recurrence-free survival in the intent-to-treat population of patients with resected stage IIIB/C/D or stage IV melanoma.